Ananda Developments

Welcome to the Ananda Developments investor hub.

At Ananda, we are focused on developing cannabinoid-based medicines to treat complex, chronic inflammatory pain conditions.

In the UK alone, 28 million people grapple with chronic pain, often facing inadequate, expensive and invasive treatments. With the NHS spending over £5 billion annually on musculoskeletal pain alone and with the global anti-inflammatory drugs market projected to reach US$191.42 billion by 2027, Ananda is poised to make a significant impact.

Backed by an increasingly robust body of clinical and real-world evidence, we believe in the potential of cannabis and its constituents to transform the treatment landscape for chronic pain.

The highest quality cannabinoid medicines, manufactured in the UK according to the strictest pharmaceutical standards

Robust clinical trial evidence by partnering with world-leading researchers

Cannabinoid medicines that are available on the NHS.

Our dynamic team boasts expertise in chronic pain and inflammation research, cannabis science, pharmaceutical R&D and equity capital markets. Collaborating with globally respected scientists, we are determined to deliver on our goals.

Thank you for your interest in Ananda Developments. Please explore our hub to stay engaged with our updates, announcements, and videos. For inquiries, our investor hub is your direct line to us. We look forward to the conversations!